Loading…
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age
In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-av...
Saved in:
Published in: | Breast cancer research and treatment 2007-11, Vol.106 (1), p.127-133 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73 |
---|---|
cites | cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73 |
container_end_page | 133 |
container_issue | 1 |
container_start_page | 127 |
container_title | Breast cancer research and treatment |
container_volume | 106 |
creator | VAN MIEGHEM, T LEUNEN, K WILDIERS, H PARIDAENS, R SMEETS, A HENDRICKX, W VAN LIMBERGEN, E CHRISTIAENS, M. R VERGOTE, I NEVEN, P POCHET, N DE MOOR, B DE SMET, F AMANT, F BERTELOOT, P TIMMERMAN, D VANDEN BEMPT, I DRIJKONINGEN, R |
description | In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression.
A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression.
There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression.
In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression. |
doi_str_mv | 10.1007/s10549-006-9474-7 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68332738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68332738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</originalsourceid><addsrcrecordid>eNqF0V1rFDEUBuAgit1Wf4A3EoR6Fz1JJl-XttRWKBSK4mXIZE5kyu7MmjMr3X_fGXeh4I1XIeQ5L-S8jL2T8EkCuM8kwTRBAFgRGtcI94KtpHFaOCXdS7YCaZ2wHuwJOyV6AIDgILxmJ3IG0uhmxX5ejN2ebxIR74cOH3kaOn5zdS8UH_9gxcdtRaJ-HOZn3lZMNPGchoyVb9PU4zDRX8gN8D2mOt8KT7_wDXtV0prw7fE8Yz--Xn2_vBG3d9ffLr_ciqy9m4TvFNhcOmuzCd632rRojFfoG7CpzWCKTcFnq6wrLhUwbeg8NKXNrU_J6TP28ZC7rePvHdIUNz1lXK_TgOOOovVaK6f9f6EMFrQNS-KHf-DDuKvD_ImopGqsa9SC5AHlOhJVLHFb-02q-yghLt3EQzdx7iYu3cRl5v0xeNdusHueOJYxg_MjSJTTutR5zz09u6BnabR-Am-plPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212467427</pqid></control><display><type>article</type><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</creator><creatorcontrib>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</creatorcontrib><description>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression.
A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression.
There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression.
In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-006-9474-7</identifier><identifier>PMID: 17211534</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Body fat ; Body Mass Index ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - genetics ; Breast Neoplasms - physiopathology ; Breast Neoplasms - surgery ; Cancer research ; Cancer therapies ; Estrogens ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Logistic Models ; Mammary gland diseases ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Odds Ratio ; Older people ; Oncology ; Postmenopause ; Prospective Studies ; Receptor, ErbB-2 - analysis ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Risk Assessment ; Tumors ; Up-Regulation ; Waist-Hip Ratio ; Weight</subject><ispartof>Breast cancer research and treatment, 2007-11, Vol.106 (1), p.127-133</ispartof><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</citedby><cites>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19372153$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17211534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN MIEGHEM, T</creatorcontrib><creatorcontrib>LEUNEN, K</creatorcontrib><creatorcontrib>WILDIERS, H</creatorcontrib><creatorcontrib>PARIDAENS, R</creatorcontrib><creatorcontrib>SMEETS, A</creatorcontrib><creatorcontrib>HENDRICKX, W</creatorcontrib><creatorcontrib>VAN LIMBERGEN, E</creatorcontrib><creatorcontrib>CHRISTIAENS, M. R</creatorcontrib><creatorcontrib>VERGOTE, I</creatorcontrib><creatorcontrib>NEVEN, P</creatorcontrib><creatorcontrib>POCHET, N</creatorcontrib><creatorcontrib>DE MOOR, B</creatorcontrib><creatorcontrib>DE SMET, F</creatorcontrib><creatorcontrib>AMANT, F</creatorcontrib><creatorcontrib>BERTELOOT, P</creatorcontrib><creatorcontrib>TIMMERMAN, D</creatorcontrib><creatorcontrib>VANDEN BEMPT, I</creatorcontrib><creatorcontrib>DRIJKONINGEN, R</creatorcontrib><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression.
A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression.
There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression.
In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Body fat</subject><subject>Body Mass Index</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Estrogens</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Logistic Models</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Odds Ratio</subject><subject>Older people</subject><subject>Oncology</subject><subject>Postmenopause</subject><subject>Prospective Studies</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Risk Assessment</subject><subject>Tumors</subject><subject>Up-Regulation</subject><subject>Waist-Hip Ratio</subject><subject>Weight</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqF0V1rFDEUBuAgit1Wf4A3EoR6Fz1JJl-XttRWKBSK4mXIZE5kyu7MmjMr3X_fGXeh4I1XIeQ5L-S8jL2T8EkCuM8kwTRBAFgRGtcI94KtpHFaOCXdS7YCaZ2wHuwJOyV6AIDgILxmJ3IG0uhmxX5ejN2ebxIR74cOH3kaOn5zdS8UH_9gxcdtRaJ-HOZn3lZMNPGchoyVb9PU4zDRX8gN8D2mOt8KT7_wDXtV0prw7fE8Yz--Xn2_vBG3d9ffLr_ciqy9m4TvFNhcOmuzCd632rRojFfoG7CpzWCKTcFnq6wrLhUwbeg8NKXNrU_J6TP28ZC7rePvHdIUNz1lXK_TgOOOovVaK6f9f6EMFrQNS-KHf-DDuKvD_ImopGqsa9SC5AHlOhJVLHFb-02q-yghLt3EQzdx7iYu3cRl5v0xeNdusHueOJYxg_MjSJTTutR5zz09u6BnabR-Am-plPg</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>VAN MIEGHEM, T</creator><creator>LEUNEN, K</creator><creator>WILDIERS, H</creator><creator>PARIDAENS, R</creator><creator>SMEETS, A</creator><creator>HENDRICKX, W</creator><creator>VAN LIMBERGEN, E</creator><creator>CHRISTIAENS, M. R</creator><creator>VERGOTE, I</creator><creator>NEVEN, P</creator><creator>POCHET, N</creator><creator>DE MOOR, B</creator><creator>DE SMET, F</creator><creator>AMANT, F</creator><creator>BERTELOOT, P</creator><creator>TIMMERMAN, D</creator><creator>VANDEN BEMPT, I</creator><creator>DRIJKONINGEN, R</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><author>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Body fat</topic><topic>Body Mass Index</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Estrogens</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Logistic Models</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Odds Ratio</topic><topic>Older people</topic><topic>Oncology</topic><topic>Postmenopause</topic><topic>Prospective Studies</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Risk Assessment</topic><topic>Tumors</topic><topic>Up-Regulation</topic><topic>Waist-Hip Ratio</topic><topic>Weight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN MIEGHEM, T</creatorcontrib><creatorcontrib>LEUNEN, K</creatorcontrib><creatorcontrib>WILDIERS, H</creatorcontrib><creatorcontrib>PARIDAENS, R</creatorcontrib><creatorcontrib>SMEETS, A</creatorcontrib><creatorcontrib>HENDRICKX, W</creatorcontrib><creatorcontrib>VAN LIMBERGEN, E</creatorcontrib><creatorcontrib>CHRISTIAENS, M. R</creatorcontrib><creatorcontrib>VERGOTE, I</creatorcontrib><creatorcontrib>NEVEN, P</creatorcontrib><creatorcontrib>POCHET, N</creatorcontrib><creatorcontrib>DE MOOR, B</creatorcontrib><creatorcontrib>DE SMET, F</creatorcontrib><creatorcontrib>AMANT, F</creatorcontrib><creatorcontrib>BERTELOOT, P</creatorcontrib><creatorcontrib>TIMMERMAN, D</creatorcontrib><creatorcontrib>VANDEN BEMPT, I</creatorcontrib><creatorcontrib>DRIJKONINGEN, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN MIEGHEM, T</au><au>LEUNEN, K</au><au>WILDIERS, H</au><au>PARIDAENS, R</au><au>SMEETS, A</au><au>HENDRICKX, W</au><au>VAN LIMBERGEN, E</au><au>CHRISTIAENS, M. R</au><au>VERGOTE, I</au><au>NEVEN, P</au><au>POCHET, N</au><au>DE MOOR, B</au><au>DE SMET, F</au><au>AMANT, F</au><au>BERTELOOT, P</au><au>TIMMERMAN, D</au><au>VANDEN BEMPT, I</au><au>DRIJKONINGEN, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>106</volume><issue>1</issue><spage>127</spage><epage>133</epage><pages>127-133</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression.
A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression.
There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression.
In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>17211534</pmid><doi>10.1007/s10549-006-9474-7</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2007-11, Vol.106 (1), p.127-133 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_proquest_miscellaneous_68332738 |
source | Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List |
subjects | Age Factors Aged Aged, 80 and over Biological and medical sciences Body fat Body Mass Index Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - genetics Breast Neoplasms - physiopathology Breast Neoplasms - surgery Cancer research Cancer therapies Estrogens Female Gene expression Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics Humans Immunohistochemistry In Situ Hybridization, Fluorescence Logistic Models Mammary gland diseases Medical sciences Metabolic diseases Middle Aged Obesity Odds Ratio Older people Oncology Postmenopause Prospective Studies Receptor, ErbB-2 - analysis Receptor, ErbB-2 - genetics Receptors, Estrogen - analysis Receptors, Progesterone - analysis Risk Assessment Tumors Up-Regulation Waist-Hip Ratio Weight |
title | Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A44%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Body%20mass%20index%20and%20HER-2%20overexpression%20in%20breast%20cancer%20patients%20over%2050%20years%20of%20age&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=VAN%20MIEGHEM,%20T&rft.date=2007-11-01&rft.volume=106&rft.issue=1&rft.spage=127&rft.epage=133&rft.pages=127-133&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-006-9474-7&rft_dat=%3Cproquest_cross%3E68332738%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212467427&rft_id=info:pmid/17211534&rfr_iscdi=true |